Medical device manufacturer VentiV Scientific has secured FDA clearance for its innovative Mechanical Thrombectomy system, including the VentiV Pulse platform, marking a significant advancement in blood clot removal technologies.
The new system addresses critical challenges in thrombectomy procedures across various medical conditions, including acute myocardial infarction, acute ischemic stroke, peripheral arterial disease, and deep vein thrombosis. The technology aims to reduce patient complications and improve treatment outcomes by offering more precise and controlled clot removal.
Key features of the VentiV Pulse platform include the ability to instantly adjust thrombectomy force, minimize catheter clogging, and reduce blood loss during procedures. The system includes 18 large-lumen catheter systems designed to address diverse clinical needs and potentially reduce procedural costs.
Current thrombectomy procedures typically involve accessing blood vessels, tracking catheters to blood clots, and applying suction through various mechanisms. Electric pump-based systems often face challenges with blood loss and flow control, which the VentiV system seeks to mitigate.
The FDA clearance represents a potential breakthrough in vascular intervention, offering medical professionals more sophisticated tools for treating complex blood clot-related conditions. By providing greater control and precision in clot removal, the system could significantly improve patient outcomes and reduce potential complications associated with traditional thrombectomy methods.
